Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2001847 | 0.91 | MAPT (0.50) | MAPTRAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL1998056 | 0.90 | MAPT (0.51) | MAPTRAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL1999173 | 0.90 | KDM4E (0.55) | MAPTRAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL1994848 | 0.89 | RAB9A (0.58) | MAPTRAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL2003083 | 0.86 | MAPT (0.55) | MAPTRAB9AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL1997641 | 0.85 | MAPT (0.52) | MAPTRAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL2001916 | 0.84 | RAB9A (0.47) | MAPTRAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL2001152 | 0.82 | CNR1 (0.56) | MAPTRAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL2003685 | 0.81 | MAPT (0.53) | MAPTRAB9AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL2002149 | 0.79 | CPT1A (0.58) | MAPTRAB9ANPC1SMN1; SMN2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | claimed |
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| WO-2009035997-A2 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CNR1, CNR2, TRPV1 | MAPT 1743/4885RAB9A 1428/4885NPC1 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.